$QTRX

Meadows Benjamin purchased $10K of QTRX

Meadows Benjamin (Chief Commercial Officer) purchased 3,500 shares of Quanterix Corp (QTRX) at $2.77 on 2026-05-12.

Original reporting
SEC EDGAR · Meadows Benjamin
Published Jun 12, 2026, 9:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 9:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$QTRX
Bullish
medium confidence
Mentioned
$QTRX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QTRXBullishLow
01

Why it matters

The newest concrete fact is the officer’s open-market purchase details (shares, price, total value) disclosed via EDGAR; it does not include any new company performance or outlook information.

02

Market read

Traders may view the insider buy as a small positive sentiment datapoint, but it is unlikely to drive a major repricing without accompanying fundamental catalysts.

03

What to watch

The filing shows the buy date (2026-05-12) and current filing date (2026-06-12); price reaction may already have occurred, reducing incremental trading value.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-12; transaction dated 2026-05-12

Background

This is an SEC Form 4 insider transaction disclosure for Quanterix (QTRX).

Company-level read

Ticker impact

$QTRXBullishMedium confidence
Context

Quanterix insider Meadows Benjamin (Chief Commercial Officer) filed an open-market purchase of 3,500 shares at $2.77 on 2026-05-12.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

Insider open-market purchases can be mildly supportive, but this filing provides no guidance, trial, contract, or regulatory development—only a small transaction size and no 10b5-1 plan context.

Market effects

No direct sector read-across; this is company-specific insider ownership activity.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine diversification or compensation-related and may not signal improved fundamentals, especially without a 10b5-1 plan.

Key entities

  • Quanterix Corp

    Subject of the Form 4 insider transaction disclosure.

  • Meadows Benjamin

    Chief Commercial Officer who purchased shares in an open-market transaction.

Related articles

$TTRXMedAI 8/10

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.